1R
1RV.F Rhythm Pharmaceuticals Inc
- Market cap
- EUR 6.76B
- P/E
- -
- P/B
- 85.86x
- ROE
- -96.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1RV.F undervalued?
Graham numberThe Graham number of Rhythm Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rhythm Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Rhythm Pharmaceuticals Inc yet.
Rhythm Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesi…
Full company profileRhythm Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rhythm Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 35.0K | 3.15M | 23.6M | 77.4M | 130M | 190M | 298M |
| Gross Profit | - | - | - | - | 0.00 | 2.56M | 21.5M | 68.1M | 117M | 170M | 260M |
| Operating Income | -25.9M | -32.4M | -78.4M | -146M | -137M | -170M | -179M | -184M | -266M | -192M | -187M |
| EBITDA | - | -32.2M | -78.0M | -145M | -136M | -169M | -176M | -168M | -238M | -174M | -174M |
| Net Income | -25.9M | -33.7M | -74.1M | -141M | -134M | -69.6M | -181M | -185M | -261M | -197M | -195M |
| EPS | - | -1.24 | -2.15 | -3.20 | -3.03 | -1.38 | -3.20 | -3.11 | -4.18 | -2.92 | -2.81 |
| Balance Sheet | |||||||||||
| Total Assets | 12.3M | 152M | 260M | 309M | 187M | 330M | 382M | 333M | 392M | 480M | 443M |
| Total Liabilities | 5.04M | 6.95M | 14.0M | 27.5M | 20.5M | 45.4M | 118M | 163M | 228M | 210M | 242M |
| Shareholders' Equity | 7.30M | 145M | 246M | 281M | 167M | 284M | 264M | 170M | 165M | 270M | 202M |
| Cash & Short-term Investments | 6.54M | 34.2M | 49.5M | 62.3M | 101M | 59.2M | 128M | 60.1M | 89.1M | 54.3M | 40.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -23.2M | -29.5M | -62.1M | -123M | -122M | -146M | -173M | -141M | -114M | -116M | -75.2M |
| Capital Expenditure | 1.06M | 133K | 722K | 3.39M | 214K | 434K | 281K | 47.0K | 0.00 | 953K | 0.00 |
| Free Cash Flow | - | -29.6M | -62.8M | -126M | -122M | -151M | -178M | -141M | -114M | -117M | -75.9M |
| Ratios | |||||||||||
| ROE | -354.6% | -23.3% | -30.1% | -50.1% | -80.5% | -24.5% | -68.5% | -108.8% | -158.4% | -72.8% | -96.8% |
| ROA | -209.7% | -22.2% | -28.5% | -45.6% | -71.6% | -21.1% | -47.4% | -55.5% | -66.4% | -40.9% | -44.0% |
| Net Profit Margin | - | - | - | - | -382,845.7% | -2,207.1% | -766.2% | -238.5% | -200.3% | -103.6% | -65.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Rhythm Pharmaceuticals Inc dividends
Rhythm Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Rhythm Pharmaceuticals Inc
- Insiders 0.70%
- Institutions 99.31%
- Public & others 0.00%
- Shares outstanding 69.3M
- Free float 56.5M
Rhythm Pharmaceuticals Inc company profile
- Company name
- Rhythm Pharmaceuticals Inc
- Ticker
- 1RV.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 414
- Fiscal year end
- December
- Address
- 222 Berkeley Street, Boston, MA, United States, 02116
- Phone
- 857 264 4280
- Website
- rhythmtx.com
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm Pharmaceuticals Inc management
10- Dr. David P. Meeker M.D.Chairman, President & CEO · born 1954
- Mr. Hunter C. Smith M.B.A.CFO & Treasurer · born 1969
- Dr. Alastair Garfield Ph.D.Chief Scientific Officer · born 1980
- Mr. Yann MazabraudExecutive VP & Head of International · born 1973
- Ms. Jennifer LeeExecutive VP & Head of North America · born 1975
- Mr. Christopher P. GermanCorporate Controller & Principal Accounting Officer · born 1972
- Mr. Joseph ShulmanChief Technical Officer · born 1975
- Mr. David ConnollyHead of Investor Relations & Corporate Communications
- Mr. Jim FlahertySenior VP & General Counsel
- Ms. Sarah RyanVice President of Sales & Marketing